Home | RheumNow

Recent News

Mixed Drinks, Mixed Results (10.30.2026)
Save

Jack Cush, MD

Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast – hopeful guidelines for PMR, certainty about good & bad beverages in gout; Mixed results in Sjogrens, non Lupus drugs saves Lupus lives and big hips sinks ships in Psoriatic arthritis.

Read Article

Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV

🚨NOW IN THE POSTER HALL: Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years Check out the data in RA, PsA, AS, and nr-axSpA presented at EULAR 2026: https://t.co/QdAKpL3Vjv Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/VYBvGp7Wnd

Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21…

Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes. Type 1 & 2 often coexist but type 2 SLE impacts QOL. @RheumNow #lupus #APLAR2026 https://t.co/aMtoIprPWG

https://x.com/RHEUMarampa/status/2115970283438051839/photo/1

Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash https://t.co/QImSxM7Izi

https://x.com/JihaRheum/status/2115969557945032869/photo/1

24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis https://t.co/cUNMo2ngeE and liver safety over time is?

24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) …

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Ass…

Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow

number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now

Chan Hong Kong prediction CRS 80/20 - 80% CRS 20% hypoxia hypotension etc predictors 4 groups b cell load and IL6 level APLAR Seoul 2026 #CART #RheumNow https://t.co/Q3C9RaYPFz

https://x.com/drpnash/status/2115705509844336813/photo/1

Georg Schett : cure prime goal of therapy! remission off all treatment , APLAR Seoul 2026 #CART #RheumNow https://t.co/kygOGdxUSe

https://x.com/drpnash/status/2115698926141726949/photo/1

lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy APLAR Seoul 2026 #CAR-T #Rheum Now

Raff - Creative - lipid nanoparticle delivery APLAR Seoul 2026 #CART #RheumNow https://t.co/1O11I5pR8P

https://x.com/drpnash/status/2115707989630058734/photo/1

“Complex to manage” in SLE not for biologics APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs

https://x.com/drpnash/status/2115998694860574864/photo/1

ExVivo advantages APLAR Seoul 2026 #CART #RheumNow https://t.co/db2jIVDaik

https://x.com/drpnash/status/2115695925641511134/photo/1

why biologics for “refractory”only - a life on steroids HCO MMF etc? APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/Fa58nsF5Mk

https://x.com/drpnash/status/2115997515338379749/photo/1

Prof. Sandra Navarra on GCs in #lupus : “There is NO safe threshold for Prednisone” Pred use follows a linear risk: As the dose of prednisone increases, damage risk doubles - - - > higher cataract, fracture and CV risks! @RheumNow #APLAR2026 https://t.co/8GGrwkcd8Q

Saag GIOP guidelines APLAR Seoul 2026 #GIOP #RheumNow https://t.co/HIEHcaQDeO

https://x.com/drpnash/status/2116001702998642747/photo/1

Oswestry Disability Index in axSpA (n=107, India): a patient-reported, low-cost, quick tool that tracked closely with BASDAI (r=0.77), BASFI (r=0.80) and ASDAS-CRP (r=0.79). Could help where rheumatologists are scarce. P#478 #APLAR26 @RheumNow https://t.co/teoMtnM3Gl

https://x.com/JihaRheum/status/2115985118280224811/photo/1

evidence T2T in SLE is wortwhile APLAR Seoul 2026 Nikpour #SLE #RheumNow

Video

Podcasts

Mixed Drinks, Mixed Results (10.30.2026)
Oct 30, 2026
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Oct 28, 2026
Double Trouble (10.23.2026)
Oct 23, 2026
Troubles with ‘Gut Feelings’
Oct 16, 2026

Submit your Rheumatology question or case here

Therapeutic Updates

Clinical dilemmas in axSpA and PsA

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Sponsored by AbbVie Medical Affairs + Health Impact

Oct 01, 2026

Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.

Read Post

Rheumnow Survey

In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE):

Hydrochlorothiazide

11%

Proton-pump inhibitors

16%

Calcium-channel blockers

TNF inhibitors

18%

Checkpoint inhibitors

I have not seen one this year

47%

Vote

Topics

Recent News

Mixed Drinks, Mixed Results (10.30.2026)
Save

Video

Podcasts

Therapeutic Updates

Clinical dilemmas in axSpA and PsA

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Obesity – Inflammation – PsA

Poster Hall

GCA Flares With a JAKi in the Second Year of SELECT-GCA

Daily Download

GLP-1 Receptor Agonists in Rheumatology

Rheumnow Survey

In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE):

Do you get our email newsletter?